keyword
MENU ▼
Read by QxMD icon Read
search

Retinal vein occlusion

keyword
https://www.readbyqxmd.com/read/28230055/corrigendum-optical-coherence-tomography-angiography-microvascular-findings-in-macular-edema-due-to-central-and-branch-retinal-vein-occlusions
#1
Rodolfo Mastropasqua, Lisa Toto, Luca Di Antonio, Enrico Borrelli, Alfonso Senatore, Marta Di Nicola, Giuseppe Di Martino, Marco Ciancaglini, Paolo Carpineto
No abstract text is available yet for this article.
February 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28221256/evaluation-of-macular-ischemia-in-eyes-with-branch-retinal-vein-occlusion-an-optical-coherence-tomography-angiography-study
#2
Shin Kadomoto, Yuki Muraoka, Sotaro Ooto, Yuko Miwa, Yuto Iida, Kiyoshi Suzuma, Tomoaki Murakami, Rima Ghashut, Akitaka Tsujikawa, Nagahisa Yoshimura
PURPOSE: To quantitatively assess macular morphology and perfusion status using optical coherence tomography, and optical coherence tomography angiography in eyes with branch retinal vein occlusion when macular edema has completely resolved, and to investigate the impact on visual function. METHODS: Thirty consecutive eyes with branch retinal vein occlusion-macular edema that resolved after treatment with intravitreal ranibizumab injections were included. Macular sensitivity was measured by microperimetry; defect length of foveal ellipsoid zone band was measured using optical coherence tomography; foveal avascular zone and parafoveal nonperfusion areas (NPA) were measured by optical coherence tomography angiography...
February 17, 2017: Retina
https://www.readbyqxmd.com/read/28219426/pseudophakic-cystoid-macular-edema-prevention-and-risk-factors-prospective-study-with-adjunctive-once-daily-topical-nepafenac-0-3-versus-placebo
#3
Sean McCafferty, April Harris, Corin Kew, Tala Kassm, Lisa Lane, Jason Levine, Meisha Raven
BACKGROUND: Define the effectiveness of a topical non-steroidal anti-inflammatory drug (NSAID) added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema (PCME) using a prospective, randomized, double-masked, placebo-controlled clinical study. METHODS: Eyes (1000) were randomized to placebo (497) or nepafenac 0.3% (503) used once daily, post-operatively for 5 weeks at two ophthalmology clinics. Diagnosis of PCME was made by clinical, ocular coherence tomography (OCT), and with fluorescein angiography confirmation...
February 20, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28214955/ranibizumab-versus-aflibercept-for-macular-edema-due-to-central-retinal-vein-occlusion-18-month-results-in-real-life-data
#4
Irini Chatziralli, George Theodossiadis, Marilita M Moschos, Panagiotis Mitropoulos, Panagiotis Theodossiadis
PURPOSE: The objective of this study was to compare the anatomical and functional outcomes of ranibizumab versus aflibercept for the treatment of macular edema due to central retinal vein occlusion (CRVO) in routine clinical practice. METHODS: Participants in this observational study included 62 treatment-naïve patients with CRVO who received intravitreal injections of either ranibizumab or aflibercept. The demographic data, best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) characteristics were evaluated at baseline and at months 1, 2, 3, 6, 12 and 18 post-treatment...
February 18, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28207609/ischemic-central-retinal-vein-occlusion-in-the-anti-vascular-endothelial-growth-factor-era
#5
Emily K Tam, Pamela Golchet, Madeline Yung, Francis C DeCroos, Marc Spirn, Lydia Lehmann-Clarke, Aude Ambresin, Irena Tsui
PURPOSE: Anti-vascular endothelial growth factor therapy has improved the prognosis for patients with central retinal vein occlusion (CRVO). However, most studies published to date exclude ischemic CRVO. The purpose of this study was to describe the outcome in eyes with ischemic CRVO treated with anti-vascular endothelial growth factor therapy. METHODS: Thirty-seven patients with ischemic CRVO from 3 centers were followed for at least 6 months. Data on patient demographic, vision status, and anti-vascular endothelial growth factor treatments were collected...
February 15, 2017: Retina
https://www.readbyqxmd.com/read/28203470/unusual-presentation-of-type-1-idiopathic-macular-telangiectasia
#6
Zaïnab Bentaleb Machkour, Philippe Denis, Laurent Kodjikian
Purpose. To report unusual presentation of type 1A idiopathic macular telangiectasia (IMT). Methods. Two middle-aged women with bilateral IMT were examined. Results. Both patients presented with a gradual vision loss in both eyes. Fundus examination was unremarkable in one case and showed small macular telangiectasia in both eyes in the other case. Fluorescein angiography (FA) revealed early bilateral macular punctuated hyperfluorescence corresponding to the dilated capillaries in both cases. FA and fundus examination confirmed also the absence of vascular abnormalities in the middle or anterior fundus periphery in one case...
2017: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/28194256/retinal-diseases-associated-with-oxidative-stress-and-the-effects-of-a-free-radical-scavenger-edaravone
#7
REVIEW
Tomomi Masuda, Masamitsu Shimazawa, Hideaki Hara
Oxidative stress plays a pivotal role in developing and accelerating retinal diseases including age-related macular degeneration (AMD), glaucoma, diabetic retinopathy (DR), and retinal vein occlusion (RVO). An excess amount of reactive oxygen species (ROS) can lead to functional and morphological impairments in retinal pigment epithelium (RPE), endothelial cells, and retinal ganglion cells (RGCs). Here we demonstrate that edaravone, a free radical scavenger, decreased apoptotic cell death, oxidative damage to DNA and lipids, and angiogenesis through inhibiting JNK and p38 MAPK pathways in AMD, glaucoma, DR, and RVO animal models...
2017: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/28192843/results-of-a-meta-analysis-on-intravitreal-anti-vegf-treatment-of-macular-oedema-secondary-to-branch-retinal-vein-occlusion-brvo
#8
H Gerding
Background In this meta-analysis, the outcome was analysed of intravitreal anti-VEGF (vascular endothelial growth factor) ocular therapy of macular oedema secondary to branch retinal vein occlusion; this was related to baseline and treatment parameters. Material and Methods 36 relevant publications (33 case series) were identified in a MEDLINE-based literature search, which reported on 1,759 treated eyes. Statistical analysis included description of baseline, treatment, and outcome data, linear and non-linear regression and comparison of randomised and non-randomised studies...
February 13, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28187470/-indications-for-retinal-laser-therapy-revisited
#9
P Enders, F Schaub, S Fauser
Background Laser therapy is an important treatment option in retinal diseases, especially in cases of vascular involvement. Most approaches are based on coagulation of retinal structures. As there is increasing use of agents targetting vascular endothelial growth factor in the treatment of macular diseases, indications for the use of laser treatment need to be reviewed carefully, especially with respect to their significance in first line therapy. This article explains recent strategies and treatment protocols...
February 10, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28185002/-multiple-thrombophilic-risk-markers-in-patients-%C3%A2-%C2%BA65%C3%A2-years-of-age-with-retinal-vein-occlusion
#10
C Kuhli-Hattenbach, P Hellstern, W Miesbach, T Kohnen, L-O Hattenbach
BACKGROUND: The potential impact of multiple thrombophilic defects on retinal venous occlusive (RVO) diseases with regard to age and various risk factors has not been studied extensively. MATERIALS AND METHODS: In a retrospective, multicenter study, thrombophilia data of 128 patients <65 years of age with RVO and 110 healthy subjects were evaluated. The main measure outcome was the prevalence of multiple thrombophilic disorders. RESULTS: Multiple thrombophilic defects were significantly more prevalent among RVO patients (18...
February 9, 2017: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/28170538/microglia-activation-and-recruitment-of-circulating-macrophages-during-ischemic-experimental-branch-retinal-vein-occlusion
#11
Andreas Ebneter, Despina Kokona, Nadia Schneider, Martin S Zinkernagel
Purpose: To characterize retinal microglia activation and macrophage recruitment in experimental branch retinal vein occlusion (BRVO). Methods: Experimental BRVO was induced in Balb/c mice and histologic changes were studied. Tissue hypoxia was visualized using pimonidazole hydrochloride. Monocyte-derived retinal cells were quantified using histology and flow cytometry. To investigate the dynamics of invading blood-borne macrophages, chimera mice were generated using bone marrow grafts from Cx3cr1(gfp/gfp) mice to rescue lethally irradiated wild-type BALB/c mice...
February 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28161829/effect-of-oral-niacin-on-central-retinal-vein-occlusion
#12
Michael W Gaynon, Yannis M Paulus, Ehsan Rahimy, Janet L Alexander, Sam E Mansour
PURPOSE: Niacin, a treatment for dyslipidemia, is known to induce vasodilation as a secondary effect. Previous instances of patients with chronic central retinal vein occlusion (CRVO) and cystoid macular edema (CME) have been observed to spontaneously improve when placed on systemic niacin for hypercholesterolemia. The purpose of this study was to evaluate the effects of niacin on CRVO and associated ocular complications. METHODS: A prospective, single-center, non-randomized, interventional case series of niacin for CRVO was conducted...
February 4, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28151838/retinal-blood-flow-after-intravitreal-bevacizumab-is-a-predictive-factor-for-outcomes-of-macular-edema-associated-with-central-retinal-vein-occlusion
#13
Makiko Matsumoto, Kiyoshi Suzuma, Yoshihisa Yamada, Eiko Tsuiki, Azusa Fujikawa, Takashi Kitaoka
PURPOSE: To investigate whether retinal blood flow levels after intravitreal bevacizumab (IVB) treatment are correlated with the outcomes of patients with macular edema secondary to central retinal vein occlusion. METHODS: This retrospective observational case study enrolled 44 cases nonischemic central retinal vein occlusion. In each patient, visual acuity, central retinal thickness, and mean blur rate, which was measured by laser speckle flowgraphy and represents retinal blood flow velocity, were examined...
February 1, 2017: Retina
https://www.readbyqxmd.com/read/28134740/relation-between-fluorescein-angiographic-and-spectral-domain-optical-coherence-tomography-findings-of-blood-flow-turbulence-at-arteriovenous-crossings-in-the-retina
#14
Anne Willerslev, Xiao Qiang Li, Inger Christine Munch, Michael Larsen
PURPOSE: To examine retinal blood flow at arteriovenous crossings using spectral-domain optical coherence tomography (SD-OCT). METHODS: Retrospective observational case series of 11 arteriovenous crossings in 10 eyes examined by SD-OCT and fluorescein angiography on suspicion of manifest or imminent branch retinal vein occlusion. RESULTS: Fluorescein angiographic evidence of turbulence was seen at 5 of 11 arteriovenous crossings, whereas laminar angiographic flow was intact at the crossing and downstream thereof at the remaining 6 crossings...
January 27, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/28127735/effects-of-panretinal-laser-photocoagulation-on-the-corneal-nerve-plexus-and-retinal-nerve-fiber-layer-in-retinal-vein-occlusion
#15
Gulfidan Bitirgen, Selman Belviranli, Rayaz A Malik, Hurkan Kerimoglu, Ahmet Ozkagnici
PURPOSE: To determine the effects of panretinal photocoagulation (PRP) on corneal sub-basal nerve plexus (SBNP) and peripapillary retinal nerve fiber layer (RNFL) thickness in patients with unilateral central retinal vein occlusion (CRVO) who had previously undergone PRP treatment. METHODS: Sixty-four eyes of 32 patients (19 male, 13 female) with unilateral ischemic type CRVO who had undergone PRP treatment at least 6 months previously were included in this cross-sectional study...
January 23, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28124146/aniseikonia-in-various-retinal-disorders
#16
Fumiki Okamoto, Yoshimi Sugiura, Yoshifumi Okamoto, Takahiro Hiraoka, Tetsuro Oshika
PURPOSE: The purpose was to quantify and compare the severity of aniseikonia in patients undergoing vitrectomy for various retinal disorders. METHODS: We studied 357 patients with retinal disorders including epiretinal membrane (ERM), macular hole (MH), cystoid macular edema with branch / central retinal vein occlusion (BRVO-CME / CRVO-CME), diabetic macular edema (DME), macula-off rhegmatogenous retinal detachment (M-off RD), and macula-on RD (M-on RD) as well as 31 normal controls...
January 25, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28114697/-strategies-of-intravitreal-injections-with-anti-vegf-pro-re-nata-versus-treat-and-extend
#17
K Hufendiek, A Pielen, C Framme
The goal of this report is to provide a review on different strategies for the use of pro re nata (PRN) and treat and extend (T&E) regimens with intravitreal anti-VEGF agents (bevacizumab, ranibizumab or aflibercept) in patients with retinal diseases such as neovascular AMD, diabetic macular oedema and macular oedema due to retinal vein occlusion. The main focus is to present the effectiveness and visual outcomes of both PRN and T&E regimens in the main pivotal trials and studies based on currently available evidence...
January 23, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28114569/optical-coherence-tomography-angiography-analysis-of-the-foveal-avascular-zone-and-macular-vessel-density-after-anti-vegf-therapy-in-eyes-with-diabetic-macular-edema-and-retinal-vein-occlusion
#18
Khalil Ghasemi Falavarjani, Nicholas A Iafe, Jean-Pierre Hubschman, Irena Tsui, Srinivas R Sadda, David Sarraf
Purpose: To evaluate the changes in foveal avascular zone (FAZ) area and the retinal capillary density after a single intravitreal anti-VEGF injection for macular edema secondary to diabetic retinopathy or retinal vein occlusion. Methods: In this prospective noncomparative case series, 18 eyes of 15 patients with diabetic macular edema (13 eyes) or macular edema secondary to central retinal vein occlusion (5 eyes) were included. Optical coherence tomography angiography (OCTA) images were obtained, and retinal capillary vessel density and FAZ area were measured in the foveal and parafoveal regions at the level of the superficial (SCP) and deep retinal capillary plexus (DCP) before and at the first visit after intravitreal injection...
January 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28107458/neuropilin-1-involvement-in-choroidal-and-retinal-neovascularisation
#19
Patricia Fernández-Robredo, Senthil Selvam, Michael B Powner, Dawn A Sim, Marcus Fruttiger
PURPOSE: Inhibiting VEGF is the gold standard treatment for neovascular age-related macular degeneration (AMD). It is also effective in preventing retinal oedema and neovascularisation (NV) in diabetic retinopathy (DR) and retinal vein occlusions (RVO). Neuropilin 1 (Nrp1) is a co-receptor for VEGF and many other growth factors, and therefore a possible alternative drug target in intra ocular neovascular disease. Here we assessed choroidal and retinal NV in an inducible, endothelial specific knock out model for Nrp1...
2017: PloS One
https://www.readbyqxmd.com/read/28106709/systemic-pharmacokinetics-and-pharmacodynamics-of-intravitreal-aflibercept-bevacizumab-and-ranibizumab
#20
Robert L Avery, Alessandro A Castellarin, Nathan C Steinle, Dilsher S Dhoot, Dante J Pieramici, Robert See, Stephen Couvillion, Maʼan A Nasir, Melvin D Rabena, Mauricio Maia, Sherri Van Everen, Kha Le, William D Hanley
PURPOSE: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO). METHODS: Prospective, open-label, nonrandomized clinical trial of patients with AMD, DME, or RVO who were antivascular endothelial growth factor (VEGF) naïve or had not received anti-VEGF for ≥4 months. Patients received 3 monthly intravitreal injections of aflibercept 2...
January 18, 2017: Retina
keyword
keyword
9749
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"